Gout and chronic kidney disease (CKD) frequently coexist, but quality evidence to guide gout management in people with CKD is lacking. Use of urate-lowering therapy (ULT) in the context of advanced CKD varies greatly, and professional bodies have issued conflicting recommendations regarding the treatment of gout in people with concomitant CKD. As a result, confusion exists among medical professionals about the appropriate management of people with gout and CKD. This Consensus Statement from the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN) discusses the evidence and/or lack thereof for the management of gout in people with CKD and identifies key areas for research to address the challenges faced in the management of gout and CKD. These discussions, which address areas for research both in general as well as related to specific medications used to treat gout flares or as ULT, are supported by separately published G-CAN systematic literature reviews. This Consensus Statement is not intended as a guideline for the management of gout in CKD; rather, it analyses the available literature on the safety and efficacy of drugs used in gout management to identify important gaps in knowledge and associated areas for research.

痛风和慢性肾脏病 (CKD) 经常共存，但缺乏指导 CKD 患者痛风管理的质量证据。在晚期 CKD 的背景下使用降尿酸治疗 (ULT) 差异很大，并且专业机构对合并 CKD 的痛风患者的治疗提出了相互矛盾的建议。因此，医疗专业人员对痛风和 CKD 患者的适当管理存在困惑。这份来自痛风、高尿酸血症和晶体相关疾病网络 (G-CAN) 的共识声明讨论了 CKD 患者痛风管理的证据和/或缺乏证据，并确定了应对管理中面临的挑战的关键研究领域痛风和 CKD。这些讨论，涉及一般研究领域以及与用于治疗痛风发作或作为 ULT 的特定药物相关的研究领域，得到了单独发表的 G-CAN 系统文献综述的支持。本共识声明并非作为 CKD 痛风管理的指南；相反，它分析了关于痛风管理中使用的药物的安全性和有效性的现有文献，以确定知识和相关研究领域的重要差距。